US2006014692A1PendingUtilityA1

Methods of using non-human animal Apoliprotein A-I protein

45
Assignee: ZHU LINGYUPriority: Jul 30, 2002Filed: Sep 8, 2005Published: Jan 19, 2006
Est. expiryJul 30, 2022(expired)· nominal 20-yr term from priority
Inventors:Lingyu ZhuNarendra LalwaniJean-Louis Dasseux
A61P 31/12A61P 9/10A61K 38/1709A61P 31/22A61K 47/6905A61P 31/18A61P 9/08A61P 31/00A61K 47/543A61P 9/00A61P 43/00A61P 31/16A61P 31/04A61P 3/06
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides methods and compositions for treating disorders using non-human animal Apolipoprotein A-I (ApoA-I) protein. The invention provides methods and compositions for treating disorders in animals, including humans, associated with dyslipidemia, including hyperlipidemia, hyperlipoproteinemia, hypertriglyceridemia, hypercholesterolemia, HDL deficiency, ApoA-I deficiency, cardiovascular disease, atherosclerosis, restenosis, and other disorders such as septic shock and viral infections.

Claims

exact text as granted — not AI-modified
1 . A method of treating a human suffering from a disorder associated with dyslipidemia, said method comprising administering to the subject an effective amount of a purified non-human animal apolipoprotein A-I protein (ApoA-I protein).  
   
   
       2 . The method of  claim 1  wherein the disorder associated with dyslipidemia is hypercholesterolemia.  
   
   
       3 . The method of  claim 1  wherein the disorder associated with dyslipidemia is cardiovascular disease.  
   
   
       4 . The method of  claim 1  wherein the disorder associated with dyslipidemia is atherosclerosis.  
   
   
       5 . The method of  claim 1  wherein the disorder associated with dyslipidemia is restenosis.  
   
   
       6 . The method of  claim 1  wherein the disorder associated with dyslipidemia is HDL or ApoA-I deficiency.  
   
   
       7 . The method of  claim 1  wherein the disorder associated with dyslipidemia is hypertriglyceridemia.  
   
   
       8 . A method of treating a subject suffering from an infection, said method comprising administering to the subject an effective amount of a purified non-human animal ApoA-I protein.  
   
   
       9 . The method of  claim 8  wherein the infection is bacterial.  
   
   
       10 . The method of  claim 9  wherein the infection is septic shock.  
   
   
       11 . The method of  claim 8  wherein the infection is viral.  
   
   
       12 . The method of  claim 11  wherein the virus is influenza.  
   
   
       13 . The method of  claim 11  wherein the virus is human immunodeficiency virus.  
   
   
       14 . The method of  claim 11  wherein the virus is cytomegalovirus.  
   
   
       15 . The method of  claim 11  wherein the virus is herpes simplex virus.  
   
   
       16 - 21 . (canceled)  
   
   
       22 . The method of  claim 1  or  8  wherein said subject is a human.  
   
   
       23 . The method of  claim 1  or  8  wherein the purified non-human animal ApoA-I protein is a bovine protein.  
   
   
       24 . The method of  claim 1  or  8  wherein the purified non-human animal ApoA-I protein is a chickens protein.  
   
   
       25 . The method of  claim 1  or  8  wherein the purified non-human animal ApoA-I protein is a turkeys protein.  
   
   
       26 . The method of  claim 1  or  8  wherein the purified non-human animal ApoA-I protein is a porcine protein.  
   
   
       27 . The method of  claim 1  or  8  wherein about 0.5 mg/kg to about 100 mg/kg of the purified non-human animal ApoA-I protein is administered to said subject.  
   
   
       28 . The method of administering the composition of  claim 27  wherein the composition is administered orally.  
   
   
       29 . The method of  claim 27  wherein the composition is administered intravenously.  
   
   
       30 . The method of  claim 27  wherein the composition is administered by inhalation.  
   
   
       31 . The method of  claim 27  wherein the composition is administered once daily.  
   
   
       32 . The method of  claim 27  wherein the composition is administered twice daily.  
   
   
       33 . The method of  claim 27  wherein the composition is administered three times daily.  
   
   
       34 . The method of  claim 27  wherein the composition is administered four times daily.  
   
   
       35 . The method of  claim 27  wherein the composition is administered about once weekly.  
   
   
       36 . The method of  claim 27  wherein the composition is administered about once monthly.  
   
   
       37 . The method of  claim 27  wherein the composition is administered about every six months.  
   
   
       38 . The method of  claim 27  wherein the composition is administered about once weekly for one month.

Join the waitlist — get patent alerts

Track US2006014692A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.